116 related articles for article (PubMed ID: 38490923)
21. Long-term and pathological outcomes of low- and intermediate-risk prostate cancer after radical prostatectomy: implications for active surveillance.
Meissner VH; Woll M; Ankerst DP; Schiele S; Gschwend JE; Herkommer K
World J Urol; 2021 Oct; 39(10):3763-3770. PubMed ID: 33973043
[TBL] [Abstract][Full Text] [Related]
22. Oncologic outcomes at 10 years following robotic radical prostatectomy.
Diaz M; Peabody JO; Kapoor V; Sammon J; Rogers CG; Stricker H; Lane Z; Gupta N; Bhandari M; Menon M
Eur Urol; 2015 Jun; 67(6):1168-1176. PubMed ID: 24996687
[TBL] [Abstract][Full Text] [Related]
23. Utility of Risk Models in Decision Making After Radical Prostatectomy: Lessons from a Natural History Cohort of Intermediate- and High-Risk Men.
Ross AE; Yousefi K; Davicioni E; Ghadessi M; Johnson MH; Sundi D; Tosoian JJ; Han M; Humphreys EB; Partin AW; Walsh PC; Trock BJ; Schaeffer EM
Eur Urol; 2016 Mar; 69(3):496-504. PubMed ID: 25922274
[TBL] [Abstract][Full Text] [Related]
24. Timing of Prostate-specific Antigen Nadir After Radical Prostatectomy and Risk of Biochemical Recurrence.
Skove SL; Howard LE; Aronson WJ; Terris MK; Kane CJ; Amling CL; Cooperberg MR; Moreira DM; Freedland SJ
Urology; 2017 Oct; 108():129-134. PubMed ID: 28735016
[TBL] [Abstract][Full Text] [Related]
25. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography.
Rigatti P; Suardi N; Briganti A; Da Pozzo LF; Tutolo M; Villa L; Gallina A; Capitanio U; Abdollah F; Scattoni V; Colombo R; Freschi M; Picchio M; Messa C; Guazzoni G; Montorsi F
Eur Urol; 2011 Nov; 60(5):935-43. PubMed ID: 21840116
[TBL] [Abstract][Full Text] [Related]
26. Effects of Initial Gleason Grade on Outcomes during Active Surveillance for Prostate Cancer.
Masic S; Cowan JE; Washington SL; Nguyen HG; Shinohara K; Cooperberg MR; Carroll PR
Eur Urol Oncol; 2018 Oct; 1(5):386-394. PubMed ID: 31158077
[TBL] [Abstract][Full Text] [Related]
27. Identification of patients at risk for biochemical recurrence after radical prostatectomy with intra-operative frozen section.
Tully KH; Schulmeyer M; Hanske J; Reike MJ; Brock M; Moritz R; Jütte H; Tannapfel A; von Bodman C; Noldus J; Palisaar RJ; Roghmann F
BJU Int; 2021 Nov; 128(5):598-606. PubMed ID: 33961328
[TBL] [Abstract][Full Text] [Related]
28. Delayed radical prostatectomy for intermediate-risk prostate cancer is associated with biochemical recurrence: possible implications for active surveillance from the SEARCH database.
Abern MR; Aronson WJ; Terris MK; Kane CJ; Presti JC; Amling CL; Freedland SJ
Prostate; 2013 Mar; 73(4):409-17. PubMed ID: 22996686
[TBL] [Abstract][Full Text] [Related]
29. Comparison of biochemical recurrence in prostate cancer patients treated with radical prostatectomy or radiotherapy.
Kim DS; Jeon SH; Chang SG; Lee SH
Korean J Urol; 2015 Oct; 56(10):703-9. PubMed ID: 26495071
[TBL] [Abstract][Full Text] [Related]
30. Comparison of robot-assisted and open retropubic radical prostatectomy for risk of biochemical progression in men with positive surgical margins.
Shapiro EY; Scarberry K; Patel T; Bergman A; Ahn JJ; Sahi N; RoyChoudhury A; Deutch I; McKiernan JM; Benson MC; Badani KK
J Endourol; 2014 Feb; 28(2):208-13. PubMed ID: 24044423
[TBL] [Abstract][Full Text] [Related]
31. Immediate versus delayed prostatectomy and the fate of patients who progress to a higher risk disease on active surveillance.
Mallya A; Senguttuvan-Karthikeyan V; Sivaraman A; Barret E; Galiano M; Cathala N; Mombet A; Prapotnich D; Sanchez-Salas R; Cathelineau X
Actas Urol Esp (Engl Ed); 2019; 43(6):324-330. PubMed ID: 30928176
[TBL] [Abstract][Full Text] [Related]
32. Do Second Primary Cancers Affect the Risk of Biochemical Recurrence in Prostate Cancer Patients Undergoing Radical Prostatectomy? A Propensity Score-Matched Analysis.
Kang M; Jung JW; Oh JJ; Lee S; Hong SK; Lee SE; Byun SS
Clin Genitourin Cancer; 2016 Aug; 14(4):e363-9. PubMed ID: 27105723
[TBL] [Abstract][Full Text] [Related]
33. Lymph node yield during radical prostatectomy does not impact rate of biochemical recurrence in patients with seminal vesicle invasion and node-negative disease.
Badani KK; Reddy BN; Moskowitz EJ; Paulucci DJ; Beksac AT; Martini A; Whalen MJ; Skarecky DW; Huynh LM; Ahlering TE
Urol Oncol; 2018 Jun; 36(6):310.e1-310.e6. PubMed ID: 29625782
[TBL] [Abstract][Full Text] [Related]
34. Long-term cancer control outcomes in patients with clinically high-risk prostate cancer treated with robot-assisted radical prostatectomy: results from a multi-institutional study of 1100 patients.
Abdollah F; Sood A; Sammon JD; Hsu L; Beyer B; Moschini M; Gandaglia G; Rogers CG; Haese A; Montorsi F; Graefen M; Briganti A; Menon M
Eur Urol; 2015 Sep; 68(3):497-505. PubMed ID: 26119559
[TBL] [Abstract][Full Text] [Related]
35. Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen era.
Isbarn H; Wanner M; Salomon G; Steuber T; Schlomm T; Köllermann J; Sauter G; Haese A; Heinzer H; Huland H; Graefen M
BJU Int; 2010 Jul; 106(1):37-43. PubMed ID: 20002667
[TBL] [Abstract][Full Text] [Related]
36. Three-year postoperative ultrasensitive prostate-specific antigen following open radical retropubic prostatectomy is a predictor for delayed biochemical recurrence.
Malik RD; Goldberg JD; Hochman T; Lepor H
Eur Urol; 2011 Sep; 60(3):548-53. PubMed ID: 21652145
[TBL] [Abstract][Full Text] [Related]
37. Obesity, prostate-specific antigen nadir, and biochemical recurrence after radical prostatectomy: biology or technique? Results from the SEARCH database.
Ho T; Gerber L; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
Eur Urol; 2012 Nov; 62(5):910-6. PubMed ID: 22921964
[TBL] [Abstract][Full Text] [Related]
38. Does Early Prostate Specific Antigen Doubling Time after Radical Prostatectomy, Calculated Prior to Prostate Specific Antigen Recurrence, Correlate with Prostate Cancer Outcomes? A Report from the SEARCH Database Group.
Teeter AE; Griffin K; Howard LE; Aronson WJ; Terris MK; Kane CJ; Amling CL; Cooperberg MR; Freedland SJ
J Urol; 2018 Mar; 199(3):713-718. PubMed ID: 28870860
[TBL] [Abstract][Full Text] [Related]
39. Comparison of MRI-Based Staging and Pathologic Staging for Predicting Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy.
Merriman KM; Harmon SA; Belue MJ; Yilmaz EC; Blake Z; Lay NS; Phelps TE; Merino MJ; Parnes HL; Law YM; Gurram S; Wood BJ; Choyke PL; Pinto PA; Turkbey B
AJR Am J Roentgenol; 2023 Dec; 221(6):773-787. PubMed ID: 37404084
[No Abstract] [Full Text] [Related]
40. Race, tumor location, and disease progression among low-risk prostate cancer patients.
Mygatt JG; Cullen J; Streicher SA; Kuo HC; Chen Y; Young D; Gesztes W; Williams G; Conti G; Porter C; Stroup SP; Rice KR; Rosner IL; Burke A; Sesterhenn I
Cancer Med; 2020 Mar; 9(6):2235-2242. PubMed ID: 31965751
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
